Autolus Therapeutics plc

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, with additional operations in Stevenage, UK, and Rockville, Maryland, USA. The company is dedicated to developing next-generation programmed T-cell therapies for the treatment of cancer and autoimmune diseases. Its mission is to engineer precisely targeted, controlled, and highly active T cell therapies designed to offer life-changing benefits to patients.

Autolus's lead product is AUCATZYL® (obecabtagene autoleucel, also known as obe-cel or AUTO1), a gene therapy consisting of autologous T cells designed to treat relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). AUCATZYL® received approval from the U.S. FDA in November 2024, conditional marketing authorization from the UK MHRA in April 2025, and is under regulatory review by the EMA. The company's pipeline also includes several other programmed T cell therapies in various stages of development for hematological malignancies, solid tumors, and autoimmune diseases, such as AUTO1/22 for pediatric ALL, obe-cel for systemic lupus erythematosus (SLE) and progressive multiple sclerosis (MS), AUTO4/5 for peripheral T-cell lymphoma, AUTO6NG for neuroblastoma, AUTO8 for multiple myeloma, and AUTO9 for acute myeloid leukemia.

In recent news, Autolus successfully launched AUCATZYL® commercially in the U.S. in 2025, generating approximately $74.3 million in net product revenue, and initiated its launch in the UK in January 2026. The company projects 2026 net product revenue for AUCATZYL® to be between $120 million and $135 million. Autolus is actively expanding the clinical utility of obe-cel into autoimmune indications, with ongoing trials for severe lupus nephritis and progressive multiple sclerosis. Dr. Christian Itin serves as the Chief Executive Officer, leading the company's efforts to build a fully-integrated, next-generation CAR T company.